Evaluation of the Efficacy of a Modified Live Escherichia coli Vaccine in Commercial Laying Hens Against Field Challenges at 23 or 44 Weeks of Age
In Indonesia, colibacillosis outbreaks in commercial layer flocks characterized by acute mortality and suboptimal egg production are still common. The aim of this study with duration of 46 weeks was to evaluate the protective effects of a modified live E. coli vaccine (Poulvac® E.coli) in laying...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article PeerReviewed |
Language: | English |
Published: |
World Veterinary Poultry Association
2019
|
Subjects: | |
Online Access: | https://repository.ugm.ac.id/277211/1/prosiding_WVPAC%20full-pages-1-3%2C6%2C15%2C26%2C207-208%2C488.pdf https://repository.ugm.ac.id/277211/ http://wvpac2019.com |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Gadjah Mada |
Language: | English |
Summary: | In Indonesia, colibacillosis outbreaks in commercial
layer flocks characterized by acute mortality and suboptimal egg production are still common. The aim of
this study with duration of 46 weeks was to evaluate
the protective effects of a modified live E. coli vaccine
(Poulvac® E.coli) in laying hens against two common
serotype of avian pathogenic E. coli (APEC), namely
O78 andO2 orlocally known as S strain. A total of 180
Isa Brown chicks raised under field condition were
divided into two groups (unvaccinated controls,
vaccinated twice at 10 days and 12 weeks of age,
respectively). All birds were challenged with either a
homologous E. coli strain (O78) or a heterologous
challenge strain (S / O2) through intra-tracheal route
(>109 mean CFU/dose). The challenge took place at
either23or44weeksofagetomimic themost common
periods of APEC infection. Efficacy was determined
based on a reduction of APEC-associated lesions and
mortality, and higher cumulative number of eggs
produced per hen housed compared to the challenged
controls. Thisstudy showed thediseasemanifestations
and mortality were pronounced in the unvaccinated
controls. Poulvac® E. coli has been demonstrated to
provide 95%and97%protection againstO78 challenge
at 23 and 44 weeks of age; 87% and 89% protection
against a heterologous E. coli S/O2 strain challenge at
two respective periods. The vaccinated layers yielded
11 more cumulative numbers of eggs per hen housed
than the unvaccinated controls.Differencesin eggshell
color and individual egg weight were also observed
in the study. |
---|